Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

January 31, 2006

Conditions
Fibromyalgia
Interventions
DRUG

Xyrem (sodium oxybate) oral solution

Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.

DRUG

Xyrem (sodium oxybate) oral solution

Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.

DRUG

Placebo

Placebo one of two doses matching active treatment by volume for 8 weeks.

Trial Locations (20)

16635

Altoona Center for Clinical Research, Duncansville

27609

C.A.R.E. Center, Raleigh

27710

Duke University Medical Center, Durham

28645

Alvin Daughtridge Arthritis Center, Lenoir

33173

Miami Research Associates, Miami

33407

Radiant Research, Inc., West Palm Beach

40509

Central Kentucky Research Associates, Inc., Lexington

44130

Cleveland Sleep Center, Middlebrook Heights

73112

Lynn Health Science Institute, Oklahoma City

77450

Abigail Rebecca Neiman, MD, Katy

78229

The University of Texas Health Science Center, San Antonio

84094

Stress Medicine Clinic -- HealthSouth Rehabilitation Hospital, Sandy City

85251

Radiant Research, Scottsdale

90048

Wallace Rheumatic Study Center, Los Angeles

90211

Osteoporosis Medical Center, Beverly Hills

97239

Oregon Health and Science University, Portland

98055

Pacific Rheumatology Research, Inc., Renton

98104

Seattle Rheumatology Associates, Seattle

71130-3932

LSU Health Sciences Center, Shreveport

07081

Richard N. Podell, MD, Springfield

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY